Full TitleAn open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment.
PDR001 is an investigational immunotherapy drug that blocks a protein called PD-1, which prevents cancer-fighting immune cells from working properly. Inhibiting PD-1 activity boosts the power of the immune system to attack cancer cells.
In this study, researchers are evaluating the safety and effectiveness of PDR001 in patients with advanced or metastatic neuroendocrine tumors of the pancreas, digestive system, thymus, or lung whose cancers have continued to grow despite prior therapy. PDR001 is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced or metastatic neuroendocrine tumor of the pancreas, digestive system, thymus, or lung that has continued to grow despite prior therapy.
- Patients must recover from the serious side effects of previous therapies before entering the study.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Nitya Raj at 646-888-4849.